Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Conditions:   Pancreatic Cancer;   Breast Cancer;   Gastric Cancer;   Non-small Cell Lung Cancer;   Cervical Cancer;   Endocervical Cancer;   Squamous Cell Carcinoma of Head and Neck;   Bladder Urothelial Cancer;   Colorectal Carcinoma;   Esophageal Cancer;   Ovarian Cancer;   Re nal Cell Carcinoma;   Prostate Cancer;   Melanoma;   Mesothelioma;   Cholangiocarcinoma Interventions:   Drug: NGM831;   Drug: NGM831 plus pembrolizumab Sponsor:   NGM Biopharmaceuticals, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials